^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    EFNB2 negative

    i
    Other names: EFNB2, Ephrin B2, HTK Ligand, Ephrin-B2, LERK5, HTKL, Eph-Related Receptor Tyrosine Kinase Ligand 5, Ligand Of Eph-Related Kinase 5, EPLG5, Htk-L, EPH-Related Receptor Tyrosine Kinase Ligand 5, MGC126226, MGC126227, MGC126228, LERK-5, EFNB2, HTK-L
    Entrez ID:
    1948
    Related biomarkers:
    Expression
    over1year
    Theranostic Potential of EFNB2 for Cetuximab Resistance in Head and Neck Cancer. (PubMed, Indian J Otolaryngol Head Neck Surg)
    Thus, EFNB2 has potential to be theranostic marker for CTX resistance. The online version contains supplementary material available at 10.1007/s12070-023-03739-9.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • EFNB2 (Ephrin B2) • IL1A (Interleukin 1, alpha) • SOCS3 (Suppressor Of Cytokine Signaling 3)
    |
    EGFR expression • EFNB2 negative • EFNB2 expression
    |
    Erbitux (cetuximab)
    3years
    Identification of Prognostic Biomarkers for Clear Cell Renal Cell Carcinoma (ccRCC) by Transcriptomics. (PubMed, Ann Clin Lab Sci)
    We constructed RS as a convincing prognostic index for ccRCC patients and found potential scientific target pathways.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • EFNB2 (Ephrin B2)
    |
    PD-1 expression • EFNB2 negative